The US Food and Drug Administration has turned down Summit Therapeutics' lung cancer drug ivonescimab, saying that holding tumours back for longer is not enough without proof that patients live longer. The agency sent Summit a complete response letter, its formal refusal, on an application to use the drug with chemotherapy in advanced lung cancer. It is a setback for a medicine that Summit licensed from its Chinese developer, Akeso, in a deal worth up to $5bn.
Ivonescimab and the FDA
- 0.76 overall survival hazard ratio from a later, post hoc look at the HARMONi trial
- 7.3% of patients stopped ivonescimab because of treatment-related side effects, against 5.0% on placebo
- $5bn top potential value of Summit's licence deal with Akeso
The FDA wanted proof that patients live longer
Summit had asked the FDA to approve ivonescimab with platinum-based chemotherapy for patients with EGFR-mutated non-small cell lung cancer that is locally advanced or has spread, and whose disease had already been treated with a third-generation EGFR tyrosine kinase inhibitor, a type of targeted drug. A complete response letter means the application cannot be approved in its current form.
The reasoning, as Summit described it, was simple. The drug improved progression-free survival, but without a statistically significant gain in overall survival, the FDA said, that did not establish substantial evidence that it works. Nor did it show a favourable balance of benefit and risk for this use.
The two measures sound alike but answer different questions. Progression-free survival tracks how long patients live before the cancer grows or spreads. Overall survival tracks how long they live, full stop. A drug can slow a tumour without moving the second number.
Summit pushed back on the bar itself. It said no regimen approved by the FDA has shown a statistically significant survival benefit in this setting.

The survival result leaned the right way but missed the mark
HARMONi was a global phase 3 trial, randomised and double-blind, meaning neither patients nor doctors knew who was getting the drug. Everyone received platinum chemotherapy; one group also got ivonescimab and the other a placebo. That design isolates what the new drug adds.
The trial had two primary goals, and it hit one: progression-free survival improved significantly. Summit said a post hoc analysis with longer follow-up for Western patients showed a benefit of similar size.
Survival was the sticking point. The main overall survival analysis favoured ivonescimab on the numbers but fell short of statistical significance. In the post hoc analysis, Summit reported a hazard ratio of 0.76 in the whole study population, in Asian patients and in Western patients alike. Put simply, patients on ivonescimab had roughly a 24% lower risk of dying over the follow-up period than those on chemotherapy alone.
"Post hoc" is the catch. It means the analysis was run after the fact, outside the test the trial was built around, so it does not count as formal proof. The FDA's stated reasoning rested on the missing significant result.
Summit said the safety profile matched earlier studies, with no new safety signals.
| Safety in HARMONi | Ivonescimab plus chemotherapy | Placebo plus chemotherapy |
|---|---|---|
| Stopped study drug due to treatment-related side effects | 16 patients (7.3%) | 11 patients (5.0%) |
| Deaths from treatment-related side effects | 4 patients (1.8%) | 5 patients (2.3%) |
A drug built to hit two targets at once
Ivonescimab is a bispecific antibody: one molecule aimed at two targets. The first is PD-1, a checkpoint that tumours exploit to switch off the immune system's attack. The second is VEGF, a signal that helps tumours grow new blood vessels. According to Summit, the antibody has four binding sites and grips PD-1 more tightly when VEGF is present.
Akeso, which is listed in Hong Kong, developed the drug, and China granted its first approval in May 2024. Akeso calls it the world's first approved bispecific antibody that combines immunotherapy and blood-vessel blocking in a single molecule. It has licensed the rights in the US and Canada, South America, Europe, the Middle East, Africa and Japan to Summit.
Maky Zanganeh, Summit's president and co-chief executive, made the case for more treatment choice from experience. "As a cancer survivor, I understand firsthand how important it is for patients to have access to multiple treatment options, particularly when they are facing diseases with significant unmet medical needs," she said.
The bigger tests are still to come
The letter covers one narrow use, in patients whose cancer has already been treated. Summit is also testing ivonescimab earlier, as a first treatment for metastatic lung cancer, and in other tumours.
Ivonescimab trials to watch
- HARMONi-3: ivonescimab plus chemotherapy as first-line treatment for metastatic lung cancer, with squamous and non-squamous tumours analysed separately
- HARMONi-7: ivonescimab on its own, first-line, for lung tumours with high levels of the PD-L1 protein
- HARMONi-GI3: ivonescimab plus chemotherapy as first-line treatment for metastatic bowel cancer that cannot be removed by surgery
- HARMONi-GU1 and SMT112-216: combinations in untreated bladder and urinary tract cancer and in clear cell kidney cancer
In a different disease, Akeso already has the kind of result the FDA asked for. On 25 October it said its HARMONi-GI1 trial in biliary tract cancer, which affects the bile ducts and gallbladder, met its primary goal of overall survival at a pre-planned interim analysis. Patients on ivonescimab plus chemotherapy lived a median 14.9 months, against 12.1 months on durvalumab plus chemotherapy, which Akeso describes as the standard of care.
Questions and answers
Why did the FDA reject ivonescimab?
According to Summit, the FDA said the gain in progression-free survival in the HARMONi trial was not enough without a statistically significant improvement in overall survival, so substantial evidence of effectiveness was not established.
What is ivonescimab?
Ivonescimab is a bispecific antibody developed by Akeso that blocks both PD-1 and VEGF. Summit Therapeutics holds the rights in the US and Canada, South America, Europe, the Middle East, Africa and Japan.
Is ivonescimab approved anywhere?
Yes, in China, where it was first approved in May 2024. It remains an investigational drug in the US.
Sources
- OncoDaily: FDA Declines Ivonescimab Plus Chemotherapy Approval in EGFR-Mutated NSCLC Following HARMONi Results
- Akeso: Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium







